Personalization and omnichannel marketing have dominated biopharma brand strategy for years, yet most brands have little to show for it.
For decades, the ‘shots on goal’ model has driven up R&D costs while failing to deliver results. Vertex Pharmaceuticals just proved there’s a better way.
Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the acquisition of Ostro.
Veeva Systems (NYSE: VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences.
Ostro co-founder Ahmed Elsayyad explains how pharma marketers can earn attention by simplifying complexity, using engaging formats, and aligning content with audience needs in a crowded digital landscape.
Veeva is acquiring agentic AI company Ostro for $100 million to boost its AI capabilities for healthcare providers and patients.
AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.
.svg)